[Hypolipidemic effect of gevilon]. / Osobennosti gipolipidemicheskogo deistviia preparata gevilona.

The drug gevilon that produces hypolipidemic effects has been clinically tested. The drug was used to treat 53 patients suffering from coronary heart disease, hypertensive disease with severe lipid metabolic disturbances. Gevilon has been found to have a hypolipidemic effect in reducing the levels of total cholesterol, beta-cholesterol, triglycerides, increasing alpha-cholesterol levels and normalizing the atherogenicity coefficient. The hypolipidemic effect of the drug is the most pronounced in Type IIb dyslipoproteinemia. Gevilon is well tolerated by patients, it can be used in combination with the drugs given in the complex therapy for coronary heart disease and hypertension.

[Phosphocreatine in the treatment of patients with myocardial infarct: effects on hemodynamics and oxygen supply]. / Fosfokreatin v lechenii bol'nykh infarktom miokarda: vliianie na gemodinamiku i kislorodnoe obespechenie organizma.

Changes in the major parameters of central and intracardiac hemodynamics and body's oxygen supply were examined in 93 patients with massive myocardial infarction in the in-hospital period of the disease. Traditional therapy was given to 71 patients; in addition, phosphocreatine infusions (a course dose being 30 g) were used in 22 patients in acute myocardial infarction. Phosphocreatine therapy failed to substantially affect cardiac pump function, but prevented left ventricular dilation and development of congestive heart failure. The patients receiving phosphocreatine showed an increase in body's oxygen consumption due to its elevated tissue extraction. No adverse effects of phosphocreatine were found.

[Possible approaches to an analysis of the heterogeneous response of the transcription complex to cholinergic actions]. / O vozmozhnykh podkhodakh k analizu geterogennoi otveta transkriptsionnogo kompleksa na kholinergicheskie vozdeistviia.

The accumulation of tyrosine-aminotransferase (TAT) as a marker of the individual gene activation was studied in the rat tissue after the administration of cholinomimetics and cholinolytics in order to elucidate the relations between cholinoreceptor functional state and the genetic apparatus. The regulation of TAT synthesis was found to be controlled by both cholinomimetic concentration and the density of cholinoreceptors in hepatocytes. Transsynaptic regulation of TAT activity was shown to be different in the brain and liver. It is suggested that the approaches discussed might be useful for the analysis of the relationship between cholinoreceptor state and the regulation of biochemical functions of target cells.